ARA290 vs KPV
ARA290, also called cibinetide, is an eleven-amino-acid non-erythropoietic peptide engineered from the helix B domain of erythropoietin to activate the innate repair receptor, an erythropoietin receptor and CD131 heteromer, without stimulating erythropoiesis. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), studied almost entirely in rodent gut inflammation and in keratinocytes. Both are described in their literatures as anti-inflammatory peptides that act without broad immunosuppression, which is the only real reason the two are set side by side. No published paper engages both. Searches of PubMed and Europe PMC across trade names, code names, sequence names and receptor terms returned no study, review, assay or method that discusses ARA290 and KPV together, so every difference set out below comes from two entirely separate bodies of work with no point of contact.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
There is no head-to-head evidence of any kind. No study has administered ARA290 and KPV in the same experiment, and, unlike most pairs in this library, not even a review, assay or analytical method names both. Searches of PubMed and Europe PMC combining cibinetide, ARA290 and the helix B surface peptide with KPV, Lys-Pro-Val and alpha-MSH(11-13) returned no records that engage the two peptides together, and searches from the receptor side, pairing the innate repair receptor with melanocortin terms, returned none either. Any comparison is therefore fully indirect. The two literatures differ in species, endpoint, clinical stage and even in the disease areas they address: cibinetide has been taken into randomised placebo-controlled phase 2 trials in sarcoidosis-associated small fibre neuropathy, painful diabetic neuropathy and diabetic macular edema, while KPV has never been given to a human participant in a published study and its principal models are murine colitis and cultured keratinocytes.
Side by side.
| ARA290 | KPV | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 7 | 6 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | An eleven-amino-acid peptide engineered from the helix B domain of erythropoietin, designed so that it activates tissue-protective signalling without the erythropoietic activity of the parent hormone. | The C-terminal three residues of alpha-melanocyte-stimulating hormone, lysine-proline-valine, described as the shortest fragment of the hormone that retains anti-inflammatory activity. |
| Mechanism as described in the literature | Activation of the innate repair receptor, a heteromer of the erythropoietin receptor and the beta-common receptor CD131, with reported anti-inflammatory effects on monocytes and macrophages and tissue protection in nerve, retina, kidney and islet models. | Uptake into intestinal epithelial and immune cells through the PepT1 di/tripeptide transporter, followed by suppression of NF-kappaB and MAPK signalling; a murine peritonitis study separated the effect from MC1R signalling. |
| Size of the evidence base | Fifteen studies in this library: five human clinical, six animal in vivo, three in vitro and one review, spanning 2011 to 2026. | Fifteen studies: ten animal in vivo, three in vitro and two reviews, spanning 2003 to 2026, with no human study of any kind. |
| Human data | Multiple completed randomised placebo-controlled phase 2 trials, in sarcoidosis-associated small fibre neuropathy, in type 2 diabetes with painful neuropathy and in diabetic macular edema, generally reporting improvement in patient-reported neuropathic symptoms and in corneal nerve fibre measures. | None. No human clinical trial of KPV has been published for colitis, wound healing, skin inflammation or any other indication. |
| Best-characterised finding | Improvement in corneal nerve fibre abundance and in neuropathic symptom scores in sarcoidosis patients with small nerve fibre loss, reported in a 28-day multicentre randomised trial in 64 subjects and supported by earlier pilot work. | PepT1-mediated uptake reducing intestinal inflammation in two mouse colitis models, reported in 2008, with reduced inflammation and tumour burden in a later murine colitis-associated cancer model. |
| Evidence maturity | Early clinical, but stalled: despite more than a decade of phase 2 work no phase 3 trial has reported and the compound has no regulatory approval in any jurisdiction. | Preclinical only, with no phase of human testing entered in the published record. |
| Relevance to the category in which each is sold | The human trials are small, short and concentrated in sarcoidosis and diabetic neuropathy. No published human study has examined ARA290 in tendon, muscle or exercise-related recovery, which is how it is marketed in this category. | The rodent work is concentrated in the gastrointestinal tract, and the recent skin work is in cultured keratinocytes. Free peptide was unstable on rectal administration, so most recent studies use engineered nanoparticles, hydrogels or microneedles rather than the plain peptide. |
| Regulatory status | No approval anywhere. Cibinetide has completed phase 2 studies under an international trial programme without a reported phase 3. | No approved product and no published regulatory assessment of the tripeptide as a medicine. |
And what it does not.
This is the emptiest pairing in the library: not only has no experiment given both peptides, no publication of any kind discusses them together. What the separate literatures support is asymmetric. ARA290 has the more developed clinical record of the two, with completed randomised placebo-controlled phase 2 trials reporting improvement in neuropathic symptoms and corneal nerve fibre measures, but those trials were small, short, confined to sarcoidosis and diabetic complications, and were never followed by a reported phase 3 or an approval. KPV has a consistent preclinical mechanism through PepT1-mediated uptake and NF-kappaB suppression, replicated across several rodent colitis models, and no human evidence at all. Both are marketed in a recovery context that neither literature addresses: no human study of ARA290 has examined musculoskeletal or exercise-related recovery, and no human study of KPV exists for any indication. Nothing published supports a preference between them.
Common questions.
- Have ARA290 and KPV ever appeared in the same publication?
No. Searches of PubMed and Europe PMC pairing cibinetide, ARA290 and the helix B surface peptide with KPV, Lys-Pro-Val and alpha-MSH(11-13) returned no records, and searches from the receptor side, combining the innate repair receptor with melanocortin terms, returned none either. Most pairs of unapproved peptides at least share a narrative review; these two do not, which reflects how far apart their research communities and disease areas sit.
- Do the two peptides converge on the same inflammatory pathway?
The published mechanisms are separate. ARA290 is described as a ligand for the innate repair receptor, a heteromer of the erythropoietin receptor and CD131, with effects reported on monocyte and macrophage activation. KPV is described as entering cells through the PepT1 di/tripeptide transporter and suppressing NF-kappaB and MAPK signalling. Both literatures describe reduced pro-inflammatory cytokine output, but no experiment has tested whether the two routes intersect downstream.
- What has cibinetide been tested for in human trials?
Randomised placebo-controlled phase 2 trials have been completed in sarcoidosis-associated small fibre neuropathy, including a 28-day multicentre study in 64 subjects using corneal confocal microscopy endpoints, in type 2 diabetes with painful neuropathy, and in diabetic macular edema over twelve weeks. Results generally showed improvement in patient-reported neuropathic symptoms and in corneal nerve fibre measures. No phase 3 trial has reported and the compound is not approved anywhere.
- Why is the KPV evidence base described as preclinical only?
Because every published efficacy finding comes from rodent models or cell culture. The core work is murine and rat colitis, colitis-associated cancer, oral mucositis and experimental traumatic brain injury, supported by keratinocyte and hepatocyte studies in vitro. No human clinical trial of KPV has been published for any indication, so human route, disposition, effective exposure and safety profile are not described in the peer-reviewed record.
- Has either peptide been studied for musculoskeletal recovery?
Neither has been studied in humans for that purpose. The ARA290 trials addressed sarcoidosis-associated neuropathy, painful diabetic neuropathy and diabetic macular edema, and no published human study has examined tendon, muscle or exercise-related recovery. The KPV literature contains no human study at all, and its animal work targets the intestine, oral mucosa and skin rather than tendon, ligament or muscle injury.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.